Jul 1, The theory of clinical endocannabinoid deficiency (CED) was presented .. correlated highly with migraine symptoms of photophobia > nausea. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other common subjective pain syndromes that lack objective signs and remain treatment resistant. Sep 27, Medical researchers have been unable to come up with a definite cause for fibromyalgia. Patients suffer from an array of debilitating symptoms.
Deficiency? Clinical Are migraines sign a of Endocannabinoid
Researchers believe that the underlying cause of many ailments, particularly those related to the immune system and inflammation, could be a disorder referred to as clinical endocannabinoid deficiency. The body naturally produces neuromodulatory lipids called endocannabinoids, which interact cannabinoid receptors throughout the body to elicit chemical responses that keep the body in balance.
Renowned cannabinoid researcher Dr. Ethan Russo first proposed the theory of clinical endocannabinoid deficiency in In a study , published in Neuro Endocrinology Letters , Russo suggested that deficient cannabinoid levels might explain why some conditions develop. Russo had examined the available literature and found evidence that people diagnosed with certain conditions had lower levels of endocannabinoids. Cannabinoids found in plants like hemp, including cannabidiol CBD , are analogous to the endocannabinoids naturally produced by the body.
Research shows that they interact with the cannabinoid receptors of the endocannabinoid system to elicit chemical responses that help bring about homeostasis.
Clinical Endocannabinoid Deficiency Reconsidered: Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. This paper has 23 citations. From This Paper Figures, tables, and topics from this paper.
Citations Publications citing this paper. Showing of 11 extracted citations. Cannabinoide in der Schmerzmedizin Prof. The endocannabinoids bind with the cannabinoid receptors in a fashion similar to other neurotransmitters and can exert various effects depending upon the lock-and-key mechanisms. They can activate the receptors as full agonists or partial agonists, or they can dock in a receptor and act as a neutral antagonist, which does not activate the receptor, or as an inverse agonist, in which case it deactivates the receptor.
The endocannabinoids are not stored in the body, but are synthesized and released on demand. The activation of these endocannabinoids influences other chemical reactions, producing a cascade effect. The ECS helps in maintaining homeostasis and has the ability to move back and forth across the synapses between cells and may exert either an excitation or inhibition of activity McPartland, Endocannabinoids serve as neurotransmitters or neuromodulators. The existence of this molecular system may explain why cannabis is helpful for such a wide array of conditions.
This study found that anandamide controls symptoms associated with clinical. Jul 11, linked to Clinical Endocannabinoid Deficiency (CED) are migraines, 3) Changes in nerve cell activity and blood flow result in symptoms. Apr 21, Clinical endocannabinoid deficiency (CECD) has been studied in scholarly ECS deficiency and medical conditions like migraines, fibromyalgia, muscles are numerous but here are some of the most common symptoms.